Intra-Cellular Therapies has been granted a patent for prodrugs of substituted heterocycle fused gamma-carbolines. The patent covers their use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), dopamine D1 and D2 receptor signaling system, and/or the µ-opioid receptor. A method for the treatment of central nervous system disorders using these compounds is also claimed. GlobalData’s report on Intra-Cellular Therapies gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Intra-Cellular Therapies Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Intra-Cellular Therapies, Peptide pharmacophores was a key innovation area identified from patents. Intra-Cellular Therapies's grant share as of September 2023 was 34%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11773095B2) discloses a method for the treatment of central nervous system disorders. The method involves administering a compound of Formula I to a patient in need of treatment. The disorders that can be treated using this method include depression, refractory depression, major depressive disorder, treatment-resistant depression, mood disorders, psychosis, schizophrenia, sleep disorders, substance addiction, substance use disorders, substance-induced disorders, obsessive-compulsive disorder (OCD), obsessive-compulsive personality disorder (OCPD), general anxiety disorder, social anxiety disorder, pain, cephalic pain, idiopathic pain, neuropathic pain, chronic pain, fibromyalgia, chronic fatigue, opiate dependency, cocaine dependency, amphetamine dependency, alcohol dependency, withdrawal from drug or alcohol dependency, and opiate overdose.

The method may also involve the administration of an agonist or partial agonist, or inverse agonist or antagonist, of the mu-opiate, kappa-opiate, delta-opiate, and/or nociceptin/orphanin receptors. Additionally, the method may include the administration of specific compounds such as buprenorphine, methadone, naloxone, or naltrexone.

The compound of Formula I can be administered in various forms, including as a pharmaceutically acceptable salt. The method may also involve the administration of a compound of Formula II, which can also be in the form of a pharmaceutically acceptable salt. These compounds can be formulated as a long-acting injectable pharmaceutical composition, in free or salt form, mixed with a pharmaceutically acceptable diluent or carrier. The long-acting injectable can be administered via subcutaneous or intramuscular injection.

This patent provides a method for treating a wide range of central nervous system disorders using specific compounds and formulations. The method offers potential benefits for patients suffering from various conditions such as depression, psychosis, sleep disorders, substance addiction, and pain. The use of specific compounds and formulations allows for targeted treatment and the potential for long-acting effects. Further research and clinical trials may be needed to validate the efficacy and safety of this method in treating central nervous system disorders.

To know more about GlobalData’s detailed insights on Intra-Cellular Therapies, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies